SCHEMBL8213818

SCHEMBL8213818

COc1ccc(Cc2ccc(C(N)=O)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 6/20 0.78
CA1 P00915 3/20 0.78
CA2 P00918 3/20 0.78
PARP4 Q9UKK3 2/20 0.78
PARP1 P09874 1/20 0.78
PARP2 Q9UGN5 1/20 0.78
PLA2G10 O15496 1/20 0.61
PLA2G2A P14555 1/20 0.61
SAE1 Q9UBE0 1/20 0.57
UBA2 Q9UBT2 1/20 0.57
VNN1 O95497 1/20 0.56
MAP4K4 O95819 1/20 0.55
LTA4H P09960 1/20 0.55
ALDH1A1 P00352 1/20 0.53
KMT2A Q03164 1/20 0.53
PARP15 Q460N3 1/20 0.53
PARP14 Q460N5 1/20 0.53
PARP16 Q8N5Y8 1/20 0.53
PARP11 Q9NR21 1/20 0.53
CES2 O00748 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201761 0.88 PARP10 (1.00) PARP10CA1CA2PARP4PARP1
SCHEMBL28127922 0.88 PARP10 (0.59) PARP10CA1CA2PARP4PARP1
Hydrochloric Acid SCHEMBL4376056 0.86 PARP10 (0.95) PARP10CA1CA2PARP4PARP1
Hydrochloric Acid SCHEMBL408766 0.86 PARP10 (0.95) PARP10CA1CA2PARP4PARP1
Ethylene Glycol SCHEMBL1232077 0.85 PARP10 (0.84) PARP10CA1CA2PARP4PARP1
SCHEMBL28232519 0.85 RAB9A (0.63) PARP10CA1CA2PARP4PARP1
SCHEMBL12339549 0.84 PARP10 (0.83) PARP10CA1CA2PARP4PARP1
SCHEMBL7134591 0.84 PLA2G10 (0.83) PARP10CA1CA2PARP4PARP1
SCHEMBL28139163 0.84 PARP1 (0.61) PARP10CA1CA2PARP4PARP1
SCHEMBL11464459 0.83 CA1 (0.77) CA1CA2SAE1UBA2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288127-A1 Novel Alkene Oxindole Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2014-09-25 US disclosed
US-8778973-B2 Alkene oxindole derivatives HOFFMANN-LAROCHE INC. (US) 2014-07-15 US disclosed
US-20130131114-A1 NOVEL ALKENE OXINDOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-23 US disclosed
EP-2480530-A1 ALKENE OXINDOLE DERIVATIVES AND THEIR USES TO TREAT OBESITY, DIABETES AND HYPERLIPIDEMIA F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011033099-A1 ALKENE OXINDOLE DERIVATIVES AND THEIR USES TO TREAT OBESITY, DIABETES AND HYPERLIPIDEMIA F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288127-A1 Novel Alkene Oxindole Derivatives PRKAB1, PRKAR2A, PRKAB2 PARP10 780/4885CA1 4752/4885CA2 3443/4885
US-20130131114-A1 NOVEL ALKENE OXINDOLE DERIVATIVES PRKAB1, PRKAR2A, PRKAB2 PARP10 780/4885CA1 4752/4885CA2 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.